The 2 Minute Medicine® Podcast

2 Minute Medicine®

Welcome to the 2 Minute Medicine® (est. 2013) Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in health care news and research evidence. Please visit our website at 2minutemedicine.com to learn more and to access all of our content including medical study summaries, visual abstracts, excerpts from our Classics book series, and The Scan, our medical newsletter. To make sure that you don’t miss any of our content please subscribe and follow us on Twitter or Instagram @2minmed.

  1. 3D AGO

    The 2 Minute Medicine® Podcast- The GLP-1 Revolution: Wegovy Pill, Lilly’s Orforglipron, and the Future of Oral Obesity Therapies

    In this special deep-dive episode of the 2 Minute Medicine® Podcast, we explore the remarkable evolution of GLP-1 receptor agonists from injectable diabetes therapies to some of the most influential drugs in modern medicine. We review the landmark clinical trials behind semaglutide and tirzepatide that transformed expectations for medical weight loss. The episode then examines the emerging race toward oral GLP-1 medications, including Novo Nordisk’s high-dose oral semaglutide and Eli Lilly’s small-molecule orforglipron. Finally, we look ahead to the next generation of metabolic therapies that may soon make once-daily pills the standard for obesity and diabetes care.

    7 min

  2. FEB 11

    The 2 Minute Medicine® Podcast- FDA Approvals, Transplant Breakthroughs, Gene Therapy Manufacturing, and ADC Safety Signals

    This Pharma Roundup episode reviews four major regulatory and clinical developments shaping early 2026. It begins with the Food and Drug Administration approval of Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for uncomplicated gonorrhea offering a needle-free alternative amid rising antimicrobial resistance. The episode then covers the approval of Yartemlea for hematopoietic stem cell transplant–associated thrombotic microangiopathy, signaling a shift toward disease-modifying therapy. It also examines the FDA’s new risk-based flexibility in Chemistry, Manufacturing, and Controls requirements for cell and gene therapies. The episode concludes with a discussion of the partial clinical hold on ifinatamab deruxtecan following safety concerns related to interstitial lung disease.

    6 min

  3. JAN 29

    The 2 Minute Medicine® Podcast- One-Dose HPV Vaccines, Oral Semaglutide, AI Deepfake Doctors, and Longevity Tech from CES 2026

    In this episode, we lead with our article of the week from the New England Journal of Medicine examining the noninferiority of a single-dose HPV vaccine compared with the standard two-dose regimen. We then dive into a detailed edition of The Scan, discussing how oral semaglutide is reshaping routine obesity visits and the real-world challenges of daily medication adherence. The conversation turns to the rise of AI deepfake doctors and the growing threat posed by counterfeit injectable medications circulating online. Next, we break down highlights from CES 2026, including new longevity-focused smart scales capable of generating sixty biomarkers in a single scan. We close with an analysis of how television medical dramas misrepresent CPR and why this portrayal may negatively affect bystander response in real-world emergencies.

    8 min

  4. 10/17/2025

    The 2 Minute Medicine® Podcast- Pharma Roundup 10/15

    In this episode of the 2 Minute Medicine Podcast: Pharma Roundup, we explore how innovation, regulation, and global strategy are reshaping the pharmaceutical landscape. We begin with the FDA’s approval of Enbumyst, the first intranasal loop diuretic for edema, offering patients with heart, kidney, or liver disease a faster and more convenient alternative to oral or intravenous therapy. Next, we turn to the FDA’s sweeping crackdown on misleading drug advertisements, marking a dramatic shift after years of lax enforcement and signaling a renewed emphasis on patient safety and transparency. We then spotlight Samsung BioLogics’ $1.3 billion U.S. contract, a deal that underscores how pharmaceutical manufacturing is adapting to tariff pressures and the need for secure biologics supply chains. Finally, we close with new data showing how Wegovy not only promotes weight loss but also reduces “food noise” and enhances mental well-being for patients, reframing obesity as both a metabolic and psychological condition. Together, these stories highlight how drug delivery, regulation, global production, and mental health insights are converging to define the next era of pharmaceutical care.

    6 min

  5. 10/15/2025

    The 2 Minute Medicine® Podcast- AI Roundup 4

    In this episode of the 2 Minute Medicine Podcast: AI Roundup, we examine how artificial intelligence is rapidly transitioning from research to real-world medical impact. We begin with Eli Lilly’s launch of TuneLab, a billion-dollar federated AI platform that opens the company’s research models to smaller biotech partners, marking a major shift toward collaborative drug discovery. Next, we explore a-Heal, a newly unveiled AI-powered smart bandage that accelerates wound healing by 25 percent in preclinical studies through algorithm-guided microcurrent therapy. From there, we turn to Punjab, India, where the state government has launched the country’s first AI-driven public health screening initiative, using thermal imaging and smart diagnostic tools to detect breast cancer, cervical cancer, and vision loss. Together, these stories capture AI’s evolution from molecule modeling to bedside innovation to population-scale screening. Each reflects how data, devices, and public policy are converging to transform the global landscape of health care.

    5 min

  6. 10/08/2025

    The 2 Minute Medicine® Podcast- Episode 61

    Welcome to this week’s episode of The 2 Minute Medicine Podcast, where practicing physicians break down the latest in clinical research and health care news. We begin with our Article of the Week, a New England Journal of Medicine study titled “Global Effect of Cardiovascular Risk Factors on Lifetime Estimates,” which analyzes data from more than two million participants across 39 countries. The findings show that individuals without common risk factors such as hypertension and smoking can gain over a decade of heart disease-free life, underscoring the importance of prevention on a global scale. In our Scan segment, we discuss the FDA’s approval of leucovorin calcium for cerebral folate deficiency and the ongoing discussion around acetaminophen use in pregnancy. We then explore the expanding world of wearable health technology, including the Oura Ring’s growing presence in both consumer and professional settings, and the questions it raises about clinical oversight. Next, we review Eli Lilly’s new oral GLP-1 medication, orforglipron, which achieved more than twelve percent weight loss in phase III trials and could make obesity treatment more accessible. Finally, we examine Florida’s evolving vaccine policy and its decision to reconsider certain school immunization requirements amid a national decline in vaccination rates. Each story highlights how innovation, regulation, and public health continue to shape the practice of modern medicine.

    9 min

  7. 09/04/2025

    The 2 Minute Medicine® Podcast- Episode 60

    In this episode, we lead with our article of the week from the New England Journal of Medicine, “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” We then cover the FDA’s authorization of updated, limited-access COVID-19 boosters and ongoing concerns about uptake. Next, we track the seasonal surge in West Nile virus during peak mosquito activity. We also discuss John Cena’s skin cancer story as a timely call for men to adopt better prevention habits. We close with how celebrity recovery narratives, from addiction to anxiety, are reshaping public conversations about mental health.

    9 min

  8. 08/29/2025

    The 2 Minute Medicine® Podcast- AI Roundup 3

    In this episode of the 2 Minute Medicine Podcast: AI Roundup, we explore how artificial intelligence is reshaping health care at every level. We begin with Illinois’ landmark law banning unsupervised AI in mental health care, the first of its kind in the U.S. We then spotlight Abridge’s $300 million funding round, as its clinical AI scribe continues to scale across more than 150 health systems. Next, we turn to DeepMind’s reflections on the limits of AI in medicine, where algorithms excel in analysis but fall short in compassion. Finally, we close with Bill Gates’ $1 million Alzheimer’s AI Prize, designed to accelerate innovation against a devastating neurodegenerative disease. Together, these stories show how policy, startups, research, and philanthropy are defining the evolving boundaries of AI in health.

    5 min
See All (70)

About

Welcome to the 2 Minute Medicine® (est. 2013) Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in health care news and research evidence. Please visit our website at 2minutemedicine.com to learn more and to access all of our content including medical study summaries, visual abstracts, excerpts from our Classics book series, and The Scan, our medical newsletter. To make sure that you don’t miss any of our content please subscribe and follow us on Twitter or Instagram @2minmed.

Information